These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22462016)

  • 1. The influence of incretin mimetics on cardiovascular risk factors in diabetes.
    Kinalska I; Bednarska-Chabowska D; Adamiec-Mroczek J; Hak L
    ISRN Endocrinol; 2012; 2012():625809. PubMed ID: 22462016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review.
    Hansen KB; Vilsbøll T; Knop FK
    Diabetes Metab Syndr Obes; 2010 May; 3():155-63. PubMed ID: 21437085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
    Siddiqui NI
    Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin mimetics as emerging treatments for type 2 diabetes.
    Joy SV; Rodgers PT; Scates AC
    Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide in the treatment of Type 2 diabetes: clinical data and practical considerations for its use.
    Ampudia-Blasco FJ; Gómez CC; Claramunt XC; Alegría JG; Gimeno EJ; Bravo JJM; Raya PM; Pérez JN; Domingo MP
    Expert Rev Endocrinol Metab; 2010 Nov; 5(6):799-807. PubMed ID: 30780828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced expression of ERp46 under diabetic conditions in β-cells and the effect of liraglutide.
    Lampropoulou E; Lymperopoulou A; Charonis A
    Metabolism; 2016 Jan; 65(1):7-15. PubMed ID: 26683792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of liraglutide in the treatment of type 2 diabetes.
    Rigato M; Fadini GP
    Diabetes Metab Syndr Obes; 2014; 7():107-20. PubMed ID: 24672252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
    Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
    Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide: a new treatment for type 2 diabetes.
    Vilsboll T
    Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
    Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
    Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs.
    Sjöholm Å
    Pharmaceuticals (Basel); 2010 Mar; 3(3):764-781. PubMed ID: 27713278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.